Gordon Powell

Gordon is a senior commercial professional with over 30 years’ experience in global life sciences focusing mainly on the IVD point of care sector but has also worked in other areas of life sciences. Most recently, Gordon was Chief Commercial Officer at genedrive plc., the in-vitro diagnostics company based in Manchester, UK, which manufactures the Genedrive point of care instrument and associated molecular assays such as TB and HCV which were targeted at LMICs. Before joining genedrive, Gordon was the Chief Executive Officer at Qnostics Ltd., a molecular control company, and prior to that was the Group Marketing Director of Axis-Shield, in London, UK, responsible for company strategy and direction as well as global sales of the Afinion POC system. It was though, as Marketing Director at Axis-Shield US that Gordon helped launch the highly successful Afinion point of care system initially through Abbott Diagnostics and then through Axis-Shield’s own sales force and PSS. Prior to that he was responsible for the strategic account management for the £9M business which included the Axis-Shield patented Homocysteine, Anti-CCP and Active B12 assays working with Abbott, Bayer, DPC and many more. Gordon also held an advisory position at biosurfit, based in Lisbon, Portugal, where he helped the company raise a €12M investment from the European Investment Bank (EIB).

Gordon is now a Non-Executive Director for EMQN and owner and Director of GRP Consulting Ltd., through which he advises and helps companies in Europe and US commercialise their products globally, as well as undertaking market research and other such services. In addition, Gordon has advised a number of university spins outs, either as a Commercial Advisor to the Board or as an external Consultant, from spin-outs from Glasgow, Strathclyde, Edinburgh, Manchester, Stanford, Oslo, and Lisbon Universities.